Enliven Therapeutics, Inc. (ELVN)
NASDAQ · Healthcare
$51.67-2.88%
As of Jul 20, 2026
Price history
Key statistics
- Market cap
- $3.65B
- P/E ratio
- —
- EPS
- —
- Volume
- 385,839
- 52-week high
- —
- 52-week low
- —
- Open
- $52.55
- Day high
- $53.45
- Day low
- $51.39
Financial highlights
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| 2025 | — | -$103.69M | -$1.83 |
| 2024 | — | -$89.02M | -$1.89 |
| 2023 | — | -$71.58M | -$2.01 |
| 2022 | — | -$37.66M | -$12.05 |
| 2021 | — | -$51.38M | -$2.37 |
About Enliven Therapeutics, Inc.
Enliven Therapeutics, Inc. is a biopharmaceutical enterprise, currently in the clinical development phase, dedicated to discovering and advancing small molecule therapeutic agents aimed at combating cancer. Its pipeline includes ELVN-001, a small molecule kinase inhibitor currently in a Phase 1 clinical trial for adult patients with chronic myeloid leukemia. Another key candidate, ELVN-002, also a small molecule kinase inhibitor, has begun a Phase 1 clinical assessment for individuals with cancers exhibiting an abnormal HER2 gene. The company's base of operations is located in Boulder, Colorado.
- CEO
- Richard A. Fair
- Employees
- 62
- Country
- US
- IPO date
- Mar 12, 2020
Similar stocks
Other Healthcare companies
Frequently asked questions
- What is Enliven Therapeutics, Inc.'s stock price today?
- ELVN is trading at $51.67 as of Jul 20, 2026.
- What is Enliven Therapeutics, Inc.'s market cap?
- Enliven Therapeutics, Inc. (ELVN) has a market capitalization of $3.65B.
- Does Enliven Therapeutics, Inc. pay a dividend?
- Enliven Therapeutics, Inc. did not pay a dividend in its most recent reported fiscal year.
- What sector is Enliven Therapeutics, Inc. in?
- Enliven Therapeutics, Inc. operates in the Healthcare sector.